https://etira.life/wp-content/uploads/2026/03/1565c5da-3105-4c13-949d-0e159581542e.jpg
521
930
Etira
https://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.png
Etira2026-03-23 11:40:282026-03-23 11:40:28ERX-41 shows activity in rare aggressive Breast Cancer subtypeBreakthroughs that
See news releases about Etira, our stellar team,
https://etira.life/wp-content/uploads/2026/03/1565c5da-3105-4c13-949d-0e159581542e.jpg
521
930
Etira
https://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.png
Etira2026-03-23 11:40:282026-03-23 11:40:28ERX-41 shows activity in rare aggressive Breast Cancer subtype
Optimization of LIPA targeting in Ovarian Cancer
NewsSan Antonio TX, February 06, 2026Introducing ERX-208 - our supercharged ERX-41 analog for ovarian cancer!Publication in Oncogene shows the same powerful MOA of inducing uncompensated ER stress, but ERX-208 delivers dramatically higher…

Etira Board Member recognized in 2026 King’s New Year Honors
NewsCongratulations to Dr Annalisa Jenkins OBE, a member of Etira’s Board of Directors, who has been appointed an Officer of the Order of the British Empire (OBE) in The King’s New Year Honours for her contributions to the life sciences.

Etira Founder’s Scientific Journey Highlighted
NewsSan Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio.

Etira CEO Featured In Clinical Leader for R&D Efficiency
NewsPhiladelphia, PA – July 16, 2025: In an article just published in Clinical Leader magazine entitled "How An Australia-First Strategy Cut 63% From Our R&D Spend", Etira CEO Russell Hayward explains how our strategic decision to conduct…

Progress in ERX-315 Phase 1 Clinical Trial
NewsDallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company aiming to develop cancer therapies, announced today that the first patient has been successfully treated at Dose Level Four (DL4) in its ongoing Phase 1 clinical…


Where to find us
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247

